FAQ
Log In
Monday 23rd January 2017
News
 › 
 › 

Study of BCG vaccination

10th April 2006

A study by Trunz, Fine and Dye, published in The Lancet, assesses and compares the cost and effect of BCG as an intervention against severe childhood tuberculosis in different regions of the world.

BCG vaccine has shown consistently high efficacy against childhood tuberculous meningitis and miliary tuberculosis, but variable efficacy against adult pulmonary tuberculosis and other mycobacterial diseases.

The study concludes that BCG vaccination should be retained in high-incidence countries as a strategy to supplement the chemotherapy of active tuberculosis as it is a highly cost-effective intervention against severe childhood tuberculosis.

 

 

 

Share this page

Comments

There are no comments for this article, be the first to comment!


Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

M3 - For secure managed hosting over N3 or internet
© Mayden Foundation 2017